JNJ vs VRTV: Which Is the Better Buy?

Side-by-side comparison of Johnson & Johnson and Veritiv Corporation β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-09-25.
Johnson & Johnson Β· Healthcare
$270.68
+5.7% upside to fair value
Med Conviction Grade C High Quality
VS
Veritiv Corporation Β· Industrials
$169.99
-45.0% upside to fair value
Med Conviction Grade D
QuantHub Verdict
JNJ has more upside to fair value (+5.7%). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric JNJ VRTV
Current Price $270.68 $169.99
Fair Value Estimate $286.05 $93.49
Upside to Fair Value +5.7% -45.0%
Market Cap $652.3B $2.3B
Forward P/E β€” β€”
EV / EBITDA 20.2x 5.4x
Price / Sales 6.7x 0.4x
Price / FCF 35.3x 10.4x
Revenue Growth YoY +6.6% -19.0%
Gross Margin 67.9% 22.7%
Operating Margin 26.8% 5.9%
Return on Equity 25.7% 48.6%
Dividend Yield 1.95% 1.48%
FCF Yield 2.83% 9.57%
Analyst Consensus Buy Hold
Investment Thesis
JNJ β€” Johnson & Johnson
Johnson & Johnson is a 141,700-employee healthcare holding company operating two segments, Innovative Medicine (immunology, oncology, neuroscience, infectious disease, cardiovascular and metabolism, pulmonary hypertension) and MedTech (interventional solutions, orthopaedics, surgery, vision), founded in 1887 and headquartered in New Brunswick, New Jersey. Business quality is high on fundamentals:…
VRTV β€” Veritiv Corporation
Veritiv Corporation is a business-to-business distributor of specialty packaging, facility solutions, print, and publishing products, operating through four segments with a network of distribution centers and roughly 5,000 employees. The business quality is mixed: it generates a strong 48.6% ROE and trades at a low 7.13 trailing P/E and 5.44 EV/EBITDA, but revenue declined 19.0% year over year in…
Accumulation Zones
Metric JNJ VRTV
Zone Low $214.54 $70.12
Zone High $243.14 $79.47
In Buy Zone? No No
← JNJ Research    VRTV Research β†’    All Research